Blockchain Registration Transaction Record

Regentis Biomaterials Advances GelrinC Cartilage Repair Technology

Regentis Biomaterials advances GelrinC, a cell-free hydrogel implant for knee cartilage repair, with strong clinical results and plans for FDA approval and European commercialization.

This news matters because Regentis Biomaterials is developing a potentially transformative solution for knee cartilage repair, a condition affecting hundreds of thousands of Americans annually with limited off-the-shelf treatment options. GelrinC’s promising clinical results, including significant pain reduction and high-quality cartilage repair scores, could offer patients a durable, long-lasting alternative to traditional microfracture surgery. As the company advances its Phase III trial and prepares for FDA approval, successful commercialization could reshape orthopedic medicine by providing a readily available, regenerative treatment that improves mobility and quality of life for patients worldwide.